158 related articles for article (PubMed ID: 27071046)
1. Alterations in Fibrin Structure in Patients with Liver Diseases.
Lisman T; Ariëns RA
Semin Thromb Hemost; 2016 Jun; 42(4):389-96. PubMed ID: 27071046
[TBL] [Abstract][Full Text] [Related]
2. Fibrin clot quality in acutely ill cirrhosis patients: Relation with outcome and improvement with coagulation factor concentrates.
Blasi A; Patel VC; Spanke ENHE; Adelmeijer J; Stamouli M; Zamalloa A; Corcoran E; Calvo A; Fernandez J; Bernal W; Lisman T
Liver Int; 2022 Feb; 42(2):435-443. PubMed ID: 34894081
[TBL] [Abstract][Full Text] [Related]
3. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen.
Hugenholtz GC; Macrae F; Adelmeijer J; Dulfer S; Porte RJ; Lisman T; Ariëns RA
J Thromb Haemost; 2016 May; 14(5):1054-66. PubMed ID: 26833718
[TBL] [Abstract][Full Text] [Related]
4. How to Assess Fibrinogen Levels and Fibrin Clot Properties in Clinical Practice?
Undas A
Semin Thromb Hemost; 2016 Jun; 42(4):381-8. PubMed ID: 27071050
[TBL] [Abstract][Full Text] [Related]
5. Additive roles of platelets and fibrinogen in whole-blood fibrin clot formation upon dilution as assessed by thromboelastometry.
Ninivaggi M; Feijge MA; Baaten CC; Kuiper GJ; Marcus MA; Ten Cate H; Lancé MD; Heemskerk JW; van der Meijden PE
Thromb Haemost; 2014 Mar; 111(3):447-57. PubMed ID: 24258426
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo addition of fibrinogen concentrate improves the fibrin network structure in plasma samples taken during liver transplantation.
Groeneveld DJ; Adelmeijer J; Hugenholtz GC; Ariëns RA; Porte RJ; Lisman T
J Thromb Haemost; 2015 Dec; 13(12):2192-201. PubMed ID: 26453059
[TBL] [Abstract][Full Text] [Related]
7. Novel mechanisms that regulate clot structure/function.
Ariëns RA
Thromb Res; 2016 May; 141 Suppl 2():S25-7. PubMed ID: 27207417
[TBL] [Abstract][Full Text] [Related]
8. Fibrin clots from patients with acute-on-chronic liver failure are weaker than those from healthy individuals and patients with sepsis without underlying liver disease.
Driever EG; Muntz I; Patel V; Adelmeijer J; Bernal W; Koenderink GH; Lisman T
J Thromb Haemost; 2023 Oct; 21(10):2747-2758. PubMed ID: 37336436
[TBL] [Abstract][Full Text] [Related]
9. Preserved clot formation detected by the Thrombodynamics analyzer in patients with cirrhosis.
Potze W; Adelmeijer J; Porte RJ; Lisman T
Thromb Res; 2015 May; 135(5):1012-6. PubMed ID: 25746364
[TBL] [Abstract][Full Text] [Related]
10. Plasma fibrin clot proteomics in healthy subjects: Relation to clot permeability and lysis time.
Ząbczyk M; Stachowicz A; Natorska J; Olszanecki R; Wiśniewski JR; Undas A
J Proteomics; 2019 Sep; 208():103487. PubMed ID: 31425886
[TBL] [Abstract][Full Text] [Related]
11. Thrombin generation and fibrin clot structure.
Wolberg AS
Blood Rev; 2007 May; 21(3):131-42. PubMed ID: 17208341
[TBL] [Abstract][Full Text] [Related]
12. Thyroid dysfunction and fibrin network structure: a mechanism for increased thrombotic risk in hyperthyroid individuals.
Hooper JM; Stuijver DJ; Orme SM; van Zaane B; Hess K; Gerdes VE; Phoenix F; Rice P; Smith KA; Alzahrani SH; Standeven KF; Ajjan RA
J Clin Endocrinol Metab; 2012 May; 97(5):1463-73. PubMed ID: 22378816
[TBL] [Abstract][Full Text] [Related]
13. Functional impact of oxidative posttranslational modifications on fibrinogen and fibrin clots.
Martinez M; Weisel JW; Ischiropoulos H
Free Radic Biol Med; 2013 Dec; 65():411-418. PubMed ID: 23851017
[TBL] [Abstract][Full Text] [Related]
14. Fibrin clot properties and thrombus composition in cirrhosis.
Driever EG; Lisman T
Res Pract Thromb Haemost; 2023 Jan; 7(1):100055. PubMed ID: 36798901
[TBL] [Abstract][Full Text] [Related]
15. Impact of fibrinogen carbamylation on fibrin clot formation and stability.
Binder V; Bergum B; Jaisson S; Gillery P; Scavenius C; Spriet E; Nyhaug AK; Roberts HM; Chapple ILC; Hellvard A; Delaleu N; Mydel P
Thromb Haemost; 2017 May; 117(5):899-910. PubMed ID: 28382370
[TBL] [Abstract][Full Text] [Related]
16. The hemostatic and thrombotic complications of liver disease.
McMurry HS; Jou J; Shatzel J
Eur J Haematol; 2021 Oct; 107(4):383-392. PubMed ID: 34258797
[TBL] [Abstract][Full Text] [Related]
17. Fibrin(ogen) as a Therapeutic Target: Opportunities and Challenges.
Gaule TG; Ajjan RA
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203139
[TBL] [Abstract][Full Text] [Related]
18. Effects of Post-Translational Modifications of Fibrinogen on Clot Formation, Clot Structure, and Fibrinolysis: A Systematic Review.
de Vries JJ; Snoek CJM; Rijken DC; de Maat MPM
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):554-569. PubMed ID: 31914791
[TBL] [Abstract][Full Text] [Related]
19. Plasma fibrin clot properties in atopic dermatitis: links between thrombosis and atopy.
Nastałek M; Wojas-Pelc A; Undas A
J Thromb Thrombolysis; 2010 Aug; 30(2):121-6. PubMed ID: 20419337
[TBL] [Abstract][Full Text] [Related]
20. The influence of fibrinogen and fibrin on thrombin generation--evidence for feedback activation of the clotting system by clot bound thrombin.
Kumar R; Béguin S; Hemker HC
Thromb Haemost; 1994 Nov; 72(5):713-21. PubMed ID: 7900079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
